A prospective cohort study of biologic and nonbiologic immunomodulators and seroconversion of COVID-19 vaccines in patients with immune-mediated inflammatory diseases
Latest Information Update: 30 Jan 2023
At a glance
- Drugs AZD 1222 (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
Most Recent Events
- 30 Jan 2023 New trial record
- 07 Dec 2022 Results published in the British Journal of Dermatology